Marek Bolanowski1, Wojciech Zgliczyński2, Jerzy Sowiński3, Agata Bałdys-Waligórska4,5, Grażyna Bednarek-Tupikowska6, Przemysław Witek2,7, Grzegorz Zieliński8, Włodzimierz Liebert9, Lucyna Siemińska10, Elżbieta Andrysiak-Mamos11, Bogdan Marek10,12, Dariusz Kajdaniuk10,12, Joanna Malicka13, Violetta Rosiek10,14, Aleksandra Jawiarczyk-Przybyłowska6, Csms Bpl Investigators. 1. Department of Endocrinology, Diabetes, and Isotope Therapy, Wrocław Medical University, Wroclaw, Poland. marek.bolanowski@umed.wroc.pl. 2. Department of Endocrinology, Medical Centre Postgraduate Education, Warszawa, Poland. 3. Department of Endocrinology, Metabolism, and Internal Medicine, University of Medical Sciences, Poznan, Poland. 4. Department of Endocrinology and Internal Medicine, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland. 5. Department of Endocrinology, Jagiellonian University, Kraków, Poland. 6. Department of Endocrinology, Diabetes, and Isotope Therapy, Wrocław Medical University, Wroclaw, Poland. 7. Department of Internal Medicine, Endocrinology, and Diabetes, Medical University of Warsaw, Warsaw, Poland. 8. Department of Neurosurgery, Military Medical Institute, Warsaw, Poland. 9. Department of Neurosurgery and Neurotraumatology, University of Medical Sciences, Poznan, Poland. 10. Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland. 11. Department of Endocrinology, Pomeranian Medical University, Szczecin, Poland. 12. Department of Endocrinology and Metabolic Diseases, Regional Hospital, Rybnik, Poland 12Department of. 13. Department of Endocrinology, Medical University, Lublin, Poland. 14. Department of Endocrinology and Neuroendocrine Tumours, Medical University of Silesia, Katowice, Poland.
Abstract
INTRODUCTION: The aim of this study was to assess the therapeutic effect and the safety of pre-surgical treatment with long-acting octreotide in patients with acromegaly. MATERIAL AND METHODS: This project was conducted in 25 centres across Poland as a non-interventional, multicentre, observational study in patients with acromegaly, in which long-acting octreotide Sandostatin® LAR®) was administered before surgery. They were 148 patients included into the study: 88 females and 60 males aged 18-86 years (51.3 ± 13.4). RESULTS: Eighty patients completed the study (underwent tumour surgery). The CRF included: baseline visit, four follow-up visits every three months before surgery, and two follow-up visits every three months after surgery. Sandostatin® LAR® was administered every four weeks. The efficacy measures were as follows: change of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels, number of patients fulfilling criteria of cure, and change of adenoma (micro- and macroadenomas) size during the treatment. Normalisation of GH and IGF-1 concentrations were obtained in 42.4 and 49.1% of patients at the end of medical therapy, respectively. Normalisation of GH and IGF-1 concentrations were obtained in 77.9 and 83.8% of patients after surgery, respectively. Reduction of microadenoma size was documented in 58.8% of patients, and in 70% of patients with macroadenomas at the end of medical therapy. In 74.0% of patients no pituitary tumour was shown on MRI after surgery. CONCLUSION: We have shown good surgical outcome in patients with acromegaly after pre-treatment with somatostatin analogue, and good tolerance and safety of the therapy, supporting the national recommendation for pre-surgical treatment with long-acting somatostatin analogues in acromegaly patients.
INTRODUCTION: The aim of this study was to assess the therapeutic effect and the safety of pre-surgical treatment with long-acting octreotide in patients with acromegaly. MATERIAL AND METHODS: This project was conducted in 25 centres across Poland as a non-interventional, multicentre, observational study in patients with acromegaly, in which long-acting octreotide Sandostatin® LAR®) was administered before surgery. They were 148 patients included into the study: 88 females and 60 males aged 18-86 years (51.3 ± 13.4). RESULTS: Eighty patients completed the study (underwent tumour surgery). The CRF included: baseline visit, four follow-up visits every three months before surgery, and two follow-up visits every three months after surgery. Sandostatin® LAR® was administered every four weeks. The efficacy measures were as follows: change of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels, number of patients fulfilling criteria of cure, and change of adenoma (micro- and macroadenomas) size during the treatment. Normalisation of GH and IGF-1 concentrations were obtained in 42.4 and 49.1% of patients at the end of medical therapy, respectively. Normalisation of GH and IGF-1 concentrations were obtained in 77.9 and 83.8% of patients after surgery, respectively. Reduction of microadenoma size was documented in 58.8% of patients, and in 70% of patients with macroadenomas at the end of medical therapy. In 74.0% of patients no pituitary tumour was shown on MRI after surgery. CONCLUSION: We have shown good surgical outcome in patients with acromegaly after pre-treatment with somatostatin analogue, and good tolerance and safety of the therapy, supporting the national recommendation for pre-surgical treatment with long-acting somatostatin analogues in acromegalypatients.
Authors: Shaun J Kilty; Myriam G M Hunink; Lisa Caulley; Eline Krijkamp; Mary-Anne Doyle; Kednapa Thavorn; Fahad Alkherayf; Nick Sahlollbey; Selina X Dong; Jason Quinn; Stephanie Johnson-Obaseki; David Schramm Journal: Pituitary Date: 2022-08-27 Impact factor: 3.599
Authors: Przemysław Witek; Marek Bolanowski; Katarzyna Szamotulska; Agnieszka Wojciechowska-Luźniak; Aleksandra Jawiarczyk-Przybyłowska; Marcin Kałużny Journal: Front Endocrinol (Lausanne) Date: 2021-03-10 Impact factor: 5.555
Authors: Małgorzata Rolla; Aleksandra Jawiarczyk-Przybyłowska; Jowita Halupczok-Żyła; Marcin Kałużny; Bogumil M Konopka; Izabela Błoniecka; Grzegorz Zieliński; Marek Bolanowski Journal: Front Endocrinol (Lausanne) Date: 2021-03-16 Impact factor: 5.555